D-galactosamine lethality model: Scope and limitations

Journal of Endotoxin Research

Volumn 10, Issue 3, 2004, Pages 147-162

  Silverstein, Richard ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

D galactosamine; D galN lethality model; TNF

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; BACTERIAL DNA; BACTERIUM LIPOPOLYSACCHARIDE; C REACTIVE PROTEIN; CEPHARANTHINE; CLINDAMYCIN; COLCHICINE; DEFEROXAMINE; DEXAMETHASONE; DIETHYLCARBAMAZINE; EBSELEN; ENDOTOXIN; FLAVONOID; FUSIDATE SODIUM; GALACTOSAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDRAZINE SULFATE; IMMUNOGLOBULIN G; LIPID A; LIPOPROTEIN; MONOCLONAL ANTIBODY; OROSOMUCOID; SCATTER FACTOR; SUPERANTIGEN; THROMBOCYTE ANTIBODY; TRYPSIN INHIBITOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; URIDINE;

ANTIINFLAMMATORY ACTIVITY; CELL PROTECTION; CYTOKINE PRODUCTION; DRUG MECHANISM; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA PNEUMONIAE; LETHAL DOSE; LETHALITY; MACROPHAGE ACTIVATION; NEISSERIA MENINGITIDIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; REVIEW; SENSITIZATION; STAPHYLOCOCCUS AUREUS; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACTERIAL TOXINS; DEXAMETHASONE; DRUG INTERACTIONS; GALACTOSAMINE; IMMUNIZATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MODELS, THEORETICAL; PROTECTIVE AGENTS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 3042775291     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805104225004879     Document Type: Review

References (198)

1. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979; 76: 5939-5943.
2. Lehmann V, Freudenberg MA, Galanos C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galN-treated mice. J Exp Med 1987; 165: 657-663.
3. Galanos C, Freudenberg MA. Tumor necrosis factor mediates endotoxin shock: the protective effects of antibodies and cortisone. In: Bonavida B, Granger G. (eds) Tumor Necrosis Factor: structure, mechanism of action, role in disease and therapy. Basel: Karger, 1990; 187-193.
4. Galanos C, Freudenberg MA, Coumbos A, Matsuura M, Lehmann V, Bartholeyns J. Induction of lethality and tolerance by endotoxin are mediated by macrophages through tumor necrosis factor. In: Bonavida B, Gifford GE, Kirchner H, Old LJ. (eds) Tumor Necrosis Factor/Cachectin and Related Cytokines. Basel: Karger, 1987; 114-127.
5. Freudenberg MA, Keppler D, Galanos C. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin. Infect Immun 1986; 51: 891-895.
6. Freudenberg MA, Galanos C. Induction of tolerance to lipopolysaccharide (LPS)-D-galN lethality by pretreatment with LPS is mediated by macrophages. Infect Immun 1986; 56: 1352-1357.
7. Michalek SM, Moore RN, McGhee JR, Rosenstreich DL, Mergenhagen SE. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin. J Infect Dis 1980; 141: 55-63.
8. Galanos C, Freudenberg MA, Katschinski, Salomao R, Mossmann H, Kumazawa Y. Tumor necrosis factor and host response to endotoxin. In: Ryan JL, Morrison DC. (eds) Bacterial Endotoxic Polysaccharide, vol II. Boca Raton, FL: CRC Press, 1992; 75-104.
9. Brown DE, Morrison DC. Possible alteration of normal mechanisms of endotoxin toxicity in vivo by actinomycin D. J Infect Dis 1982; 146: 746-750.
10. Selye H, Tuchweber B, Bertok L. Effect of lead acetate on the susceptibility of rats to bacterial endotoxin. J Bacteriol 1966; 91: 884-890.
11. Rippe DF, Berry LJ. Metabolic manifestations of lead acetate sensitization to endotoxin in mice. J Reticuloendothel Soc 1973; 13: 527-535.
12. Shands Jr JW, Miller V, Martin H. The hypoglycemic activity of endotoxin. I. Occurrence in animals hyperreactive to endotoxin. Proc Soc Exp Biol Med 1969; 130: 413-417.
13. Decker K, Keppler D. Galactosamine hepatitis: key role of the nucleotide deficiency period in the pathogensesis of cell injury and cell death. Rev Physiol Biochem Pharmacol 1974; 71: 77-106.
14. Matthys P, Mitera T, Heremans H, Van Damme J, Billiau A. Anti-gamma interferon and anti-interleukin-6 antibodies after staphylococcal enterotoxin D-induced weight loss, hypoglycemia, and cytokine release in D-galN-sensitized and unsensitized mice. Infect Immun 1995; 63: 1158-1164.
15. Bonventre PF, Heeg H, Edwards CK, Cullen CM. A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity. Infect Immun 1995; 63: 509-515.
16. Aoki Y, Hiromatsu K, Kobayashi N et al. Protective effect of granulocyte colony-stimulating factor against T-cell mediated lethal shock triggered by superantigens. Blood 1995; 86: 1420-1427.
17. Mountz JD, Baker TJ, Borcherding DR, Bluethmann H, Zhou T, Edwards CK. Increased susceptibility of fas mutant MRL-lpr/lpr mice to staphylococcal enterotoxin B-induced septic shock. J Immunol 1995; 155: 4829-4837.
18. Nagaki M, Muto Y, Ohnishi H et al. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. Gastroenterology 1994; 106: 450-458.
19. Miethke T, Wahl C, Heeg K, Wagner H. Acquired resistance to superantigen-induced T cell shock. V beta selective T cell responsiveness unfolds directly from a transient state of hyperreactivity. J Immunol 1993; 150: 3776-3884.
20. Chapes SK, Beharka AA. Lipopolysaccharide is required for the lethal effects of enterotoxin B after D-galN sensitization. J Endotoxin Res 1995; 2: 263-271.
21. Yasuda S, Nagaki M, Moriwaki H. Staphylococcal enterotoxin B induces hepatic injury and lethal shock in endotoxin-resistant C3H/HeJ mice despite a deficient macrophage response. J Endotoxin Res 2002; 8: 253-261.
22. Blank C, Luz A, Bendigs S, Erdmann A, Wagner H, Heeg K. Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol 1997; 27: 825-833.
23. Miethke T, Duschek K, Wahl C, Heeg K, Wagner H. Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol 1993; 23: 1494-1500.
24. Miethke T, Wahl C, Heeg K, Echtenacher B, Krammer PH, Wagner H. T cell mediated lethal shock triggered by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med 1992; 175: 91-98.
25. Bate CA, Taverne J, Playfaur JH. Detoxified exoantigens and phosphatidylinositiol derivatives inhibit tumor necrosis factor induction of malarial exoantigens. Infect Immun 1992; 60: 1894-1901.
26. Hellman J, Roberts Jr JD, Tehan MM, Allaire JE, Warren HS. Bacterial peptidoglycan-associated lipoprotein is released into the bloodstream in Gram-negative sepsis and causes inflammation and death in mice. J Biol Chem 2002; 277: 14274-14280.
27. Zhang H, Peterson JW, Niesel DW, Klimpel GR. Bacterial lipoprotein and lipopolysaccharide act synergistically to induce lethal shock and proinflammatory cytokine production. J Immunol 1997; 159: 4868-4878.
28. Galanos C, Gumenscheimer M, Mühltradt PF, Jirillo E, Freudenberg MA. MALP-2, a Mycoplasma lipopolypeptide with classical endotoxic properties: end of an era of LPS monopoly? J Endotoxin Res 2000, 6: 471-476.
29. Sparwasser T, Miethke T, Lipford G et al. Bacterial DNA causes septic shock. Nature 1997; 386: 336-337.
30. Cornelie S, Wiel E, Lund N et al. Cytosine-phosphate-guanine (CpG) motifs are sensitizing agents for lipopolysaccharide in toxic shock model. Intensive Care Med 2002; 9: 1340-1347.
31. Heeg K, Sparwasser T, Lipford GB, Hacker H, Zimmermnan S, Wagner H. Bacterial DNA as an energetically conserved signalling danger of infection to immune cells. Eur J Clin Microbiol Infect Dis 1998; 7: 464-469.
32. Sparwasser T, Miethke T, Lipford G et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor α -mediated shock. Eur J Immunol 1997; 27: 1671-1679.
33. Freudenberg MA, Galanos C. Tumor necrosis factor alpha mediates lethal activity of killed Gram-negative and Gram-positive bacteria in D-galN-treated mice. Infect Immun 1991; 59: 2110-2115.
34. Silverstein R, Norimatsu M, Morrison DC. Fundamental differences during Gram-positive versus Gram-negative sepsis become apparent during bacterial challenge of D-galN-treated mice. J Endotoxin Res 1997; 4: 173-181.
35. Silverstein R, Wood JG, Xue Q, Norimatsu M, Horn DL, Morrison DC. Differential host inflammatory responses to viable versus antibiotic-killed bacteria in experimental microbial sepsis. Infect Immun 2000; 68: 2301-2308.
36. Silverstein R, Johnson DC. Endogenous and exogenous glucocorticoid responses to experimental bacterial sepsis. J Leukoc Biol 2003; 73: 417-427.
37. Silverstein R, Gao JJ, Xue Q, Morrisom DC. The role of TNF-a in enterococcal infection in D-galactosamine treated mice. Shock 2002; 155: 24(Abstract #70).
38. Papasian CJ, Silverstein R, Gao JJ, Bamberger DM, Morrison DC. Anomalous role of tumor necrosis factor alpha in experimental enterococcal infection. Infect Immun 2002; 70: 6628-6637.
39. Silverstein R, Christoffersen CA, Morrison DC. Modulation of endotoxin lethality in mice by hydrazine sulfate. Infect Immun 1989; 57: 2072-2078.
40. Silverstein R, Turley BR, Christofferesen CA, Johnson DC, Morrison DC. Hydrazine sulfate protects D-galN-sensitized mice against endotoxin and tumor necrosis factor/cachectin lethality: evidence of a role for the pituitary. J Exp Med 1991; 173: 357-365.
41. Silverstein R. Uridine protection against D-galN-sensitized LPS lethality in mice is complete. J Endotoxin Res 1997; 4: 463-465.
42. Marino MW, Dunn A, Grail D et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 8093-8098.
43. Glaccum MB, Stocking KL, Charrier K et al. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1. J Immunol 1997; 159: 3364-3371.
44. Garcia I, Miyazaki Y, Araki K et al. Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections. Eur J Immunol 1995; 25: 2401-2407.
45. Rothe J, Lesslauer W, Lötscher H et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993; 364: 798-802.
46. Erickson SL, de Sauvage FJ, Kikly K et al. Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994; 372: 560-563.
47. Kolls JK, Lei D, Nelson S et al. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defense. J Infect Dis 1995; 171: 570-575.
48. Xu H, Gonzalo JA, St Pierre Y et al. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 1994; 180: 95-109.
49. Essani NA, Fisher MA, Farhood A, Manning AM, Smith CW, Jaeschke H. Cytokine-induced upregulation of hepatic intercellular adhesion molecule-1 messenger RNA expression and its role in the pathology of murine endotoxin shock and acute liver failure. Hepatology 1995; 21: 1632-1639.
50. Jaeschke H, Essani NA, Fisher MA, Vonderfecht SL, Farhood A, Smith CW. Release of soluble intercellular adhesion molecule 1 into bile and serum in murine endotoxin shock. Hepatology 1996; 23: 530-536.
51. Essani NA, Bajt ML, Farhood A, Vonderfecht SL, Jaeschke H. Transcriptional activation of vascular cell adhesion molecule-1 gene in vivo and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Immunol 1997; 158: 5941-5948.
52. Chosay JG, Fisher MA, Farhood A, Ready KA, Dunn CJ, Jaeschke H. Role of PECAM-1 (CD13) in neutrophil transmigration in murine models of liver and peritoneal inflammation. Am J Physiol 1998; 274: G776-G782.
53. Klintman D, Schramm R, Menger MD, Thorlacius. Leukocyte recruitment in hepatic injury: selectin-mediated leukocyte rolling is a prerequisite for CD18-dependent firm adhesion. J Hepatol 2002; 36: 53-59.
54. Essani NA, Fisher MA, Simmons CA, Hoover JL, Farhood A, Jaeschke H. Increased P-selectin gene expression in the liver vasculature and its role in the pathophysiology of neutrophil-induced liver injury in murine endotoxin shock. J Leukoc Biol 1998; 63; 288-296.
55. Ohuchi T, Tada K, Akamatsu K. Endogenous ET-1 contributes to liver injury induced by galactosamine and endotoxin in isolated perfused rat liver. Am J Physiol 1995; 268: G997-G1003.
56. Shindo T, Kurihara H, Kurihara Y, Morita H, Yazaki Y. Upregulation of endothelin-1 and adrenomedullin gene expression in the mouse endotoxin shock model. J Cardiovasc Pharmacol 1998; 31 (Suppl 1): S541-S544.
57. Tiegs G, Niehörster, Wendel A. Leukocyte alterations do not account for hepatitis induced by endotoxin or TNF-α in galactosamine-sensitized mice. Biochem Pharmacol 1990; 40: 1317-1322.
58. Silverstein R, Johnson WM, Bucklin SE, Johnson DC. The protein kinase C activator PMA modulates LPS lethality in normal mice and protects against LPS lethality in D-galN-sensitized mice. J Endotoxin Res 1996; 3: 29-37.
59. Amura CR, Silverstein R, Morrison DC. Mechanisms involved in the pathogenesis of sepsis are not necessarily reflected by in vitro activation studies. Infect Immun 1998; 66: 5372-5378.
60. Cusumano V, Mancuso G, Genovese F et al. Neonatal hypersensitivity to endotoxin correlates with increased tumor necrosis factor production in mice. J Infect Dis 1997; 176: 168-176.
61. Lehner MD, Morath S, Michelsen KS, Schumann RR, Hartung T. Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators. J Immunol 2001; 166: 5161-5167.
62. Gao JJ, Xue Q, Papasian CJ, Morrison DC. Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol 2001; 166: 6855-6860.
63. Wray GM, Foster SJ, Hinds CJ, Thiemermann C. A cell wall component from pathogenic and non-pathogenic Gram-positive bacteria (peptidoglycan) synergises with endotoxin to cause the release of tumour necrosis factor-α, nitric oxide production, shock, and multiple organ injury/dysfunction in the rat. Shock 2001; 15: 135-142.
64. Gao JJ, Zuvanich EG, Xue Q, Horn DL, Silverstein R, Morrison DC. Bacterial DNA and LPS act in synergy in inducing nitric oxide production in RAW 264.7 macrophages. J Immunol 1999; 163: 4095-4099.
65. Gao JJ, Diesl V, Wittmann T et al. Bacterial LPS and CpG DNA differentially induce gene expression in mouse macrophages. J Endotoxin Res 2003; 9: 237-243.
66. Yang S, Tamai R, Akashi S et al. Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 2001; 69: 2045-2053.
67. Wang JE, Jørgensen PF, Ellingsen EA et al. Peptidoglycan primes for LPS-induced release of proinflammatory cytokines in whole human blood. Shock 2001; 16: 178-182.
68. Proceedings of the Symposium: Antibiotic-mediated endotoxin release - Contribution to pathogenesis in Gram-negative sepsis. J Endotoxin Res 1995; 3: 171-279.
69. Bucklin SE, Morrison DC. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J Infect Dis 1995; 172: 1519-1527.
70. Morrison DC, Bucklin SE, Leeson MC, Norimatsu M. Contribution of soluble endotoxin released from Gram-negative bacteria by antibiotics to the pathogenesis of experimental sepsis in mice. J Endotoxin Res 1996; 3: 237-243.
71. Bucklin SE, Morrison DC. Bacteremia versus endotoxemia in experimental mouse leukopenia - role of antibiotic chemotherapy. J Infect Dis 1996; 174: 1249-1254.
72. LeRoy D, Morand P, Lengacher S et al. Streptococcus mitis cell walls and lipopolysaccharide induce lethality in D-galactosamine-sensitized mice by a tumor necrosis factor-dependent pathway. Infect Immun 1996; 64: 1846-1849.
73. Deiters U, Gumenscheimer M, Galanos C, Mühlradt PF. Toll-like receptor 2- and 6-mediated stimulation by macrophage-activating lipopeptide 2 induces lipopolysaccharide (LPS) cross tolerance in mice, which results in protection from tumor necrosis factor alpha but in only partial protection from lethal LPS doses. Infect Immun 2003; 71: 4456-4462.
74. Freudenberg MA, Salômao, Sing A, Mitov I, Galanos C. Reconciling the concepts of endotoxin sensitization and tolerance. Prog Clin Biol Res 1998; 397: 261-268.
75. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977-980.
76. Silverstein R, Johnson DC, Norimatsu M. Glucocorticoid control of endotoxin responses. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York: Dekker, 1999; 769-779.
77. Evans GF, Zuckerman SH. Glucocorticoid-dependent and -independent mechanisms involved on lipopolysaccharide tolerance. Eur J Immunol 1973; 21: 1973-1979.
78. Libert C, Hochepied T, Berger FG, Baumann H, Fiers W, Brouckaert P. High-level constitutive expression of alpha 1-acid glycoprotein and lack of protection against tumor necrosis factor-induced lethal shock in transgenic mice. Transgenic Res 1998; 7: 429-435.
79. Libert C, Van Molle W, Brouckaert P, Fiers W. Platelet-activating factor is a mediator in tumor necrosis factor/galactosamine-induced lethality. J Inflamm 1995; 46: 139-143.
80. Libert C, Brouckaert P. Fiers W. Protection by alpha 1-acid glycoprotein against tumor necrosis factor-induced lethality. J Exp Med 1994; 180: 1571-1575.
81. Wang R, Fang Q, Zhang L et al. CD28 ligation prevents toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol 1997; 158: 2856-2861.
82. Field SK, Morrison DC. An anti-idiotype antibody which mimics the inner-core region of lipopolysaccharide protects mice against a lethal challenge from endotoxin. Infect Immun 1994; 62: 3994-3999.
83. Mandine E, Salles MF, Zalisz R, Guenounou M, Smets P. Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae. Infect Immun 1990; 58: 2828-2833.
84. Gallay P, Heumann D, Le-Roy D, Barras C, Glausner MP. Mode of action of anti-lipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci USA 1994; 91: 7922-7926.
85. Ramachandra RN, Berczi A, Schon AH, Berczi I. Inhibition of lipid-A and lipopolysaccharide-induced cytokine secretion, B cell mitogenesis, and lethal shock by lipid A-specific murine monoclonal antibodies. J Infect Dis 1993; 167: 1151-1159.
86. Vacheron F, Mandine E, Lenaour R, Smets P, Zalisz R, Guenounou M. Inhibition of production of tumor necrosis factor by monoclonal antibodies to lipopolysaccharides. J Infect Dis 1992; 165: 873-878.
87. Bailat S, Heumann D, Le-Roy D et al. Similarities and disparities between core-specific and O-side-chain-specific antilipopolysaccharide monoclonal antibodies in models of endotoxemia and bacteremia in mice. Infect Immun 1997; 65: 811-814.
88. Morrison DC, Silverstein R, Bright SW, Chen TY, Flebbe LM, Lei M-G. Monoclonal antibody to mouse lipopolysaccharide receptor protects mice against the lethal effects of endotoxin. J Infect Dis 1990; 162: 1063-1068.
89. Piguet PF, Vesin C, Ryser JE et al. An effector role for platelets in systemic and local lipopolysaccharide-induced toxicity in mice, mediated by a CD11a- and CD54-dependent interaction with endothelium. Infect Immun 1993; 61: 4182-4187.
90. Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C, Fournel MA. Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 1992; 120: 574-588.
91. Grau GE, Vesin C, De-Groote D et al. Prevention of human TNF-induced cutaneous Schwartzmann reaction and acute mortality in mice treated with anti-human TNF monoclonal antibodies. Clin Exp Immunol 1991; 84: 411-414.
92. Libert C, Van-Molle W, Brouckaert P, Fiers W. Alpha 1-antitrypsin inhibits the lethal response to TNF in mice. J Immunol 1996; 157: 5126-5129.
93. Kirikae T, Hirata M, Yamasu H et al. Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect Immun 1998; 66: 1861-1868.
94. Bals R, Weiner DJ, Moscioni AD, Meegalla RL, Wilson JM. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect Immun 1999; 67: 6084-6089.
95. Furusako S, Takahashi T, Mori S et al. Protection of mice from LPS-induced shock by CD14 antisense oligonucleotide. Acta Med Okayama 2001; 55: 105-115.
96. Maruyama H, Kikuchi S, Kawaguchi B et al. Suppression of lethal toxicity of endotoxin by biscoclaurine alkaloid cepharanthin. Shock 2000; 13: 160-165.
97. Hirata N, Hiramatsu K, Kishi K, Yamasaki T, Ichimiya T, Nasu M. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother 2001; 45: 2638-2642.
98. Tiegs G. Freudenberg MA, Galanos C, Wendel A. Colchicine prevents tumor necrosis factor-induced toxicity in vivo. Infect Immun 1992; 60: 1941-1945.
99. Chae MR, Park BH, Kim JS, Rho HW, Park JW, Kim HR. Protective effect of C-reactive protein against the lethality induced by Vibrio vulnificus lipopolysaccharide. Microbiol Immunol 2000; 44: 335-340.
100. Elliot GT, Welty D, Kuo YD. The D-galactosamine loaded mouse and its enhanced sensitivity to lipopolysaccharide and monophosphoryl lipid A: a role for superoxide. J Immunother 1991; 10: 69-74.
101. Parry EW. Cycloheximide or nordihydroguaiaretic acid protects mice against the lethal and hepatocytolytic effects of a combined challenge with D-galN and bacterial endotoxin. J Comp Pathol 1993; 108: 185-190.
102. Vulcano M, Meiss RP, Isturiz MA. Deferoxamine reduces tissue injury and lethality in LPS-treated mice. Int J Immunopharmacol 2000; 8: 635-644.
103. Danenberg HD, Alpert G, Lustig S, Ben-Nathan D. Dehydroepiandosterone protects mice from endotoxin toxicity and reduces tumor necrosis factor production. Antimicrob Agents Chemother 1992; 10: 2275-2279.
104. Gonzalez JC, Johnson DC, Morrison DC, Freudenberg MA, Galanos C, Silverstein R. Endogenous and exogenous glucocorticoids have different roles in modulating endotoxin lethality in D-galN-sensitized mice. Infect Immun 1993; 61: 970-974.
105. Badger AM, Olivera D, Talmadge JE, Hanna N. Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism. In murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action. Circ Shock 1989; 27: 51-61.
106. Hagmann W, Denzlinger C, Keppler D. Role of peptide leukotrienes and their hepatobiliary elimination in endotoxin action. Circ Shock 1984; 14: 223-235.
107. Konz KH, Tiegs G, Wendel A. Protection by ebselen against endotoxin shock in rats or mice sensitized by galactosamine. Prog Clin Biol Res 1987; 236A: 281-288.
108. Dankesreiter S, Hoess A, Schneider-Mergener J, Wagner H, Miethke T. Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-alpha production by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J Immunol 2000; 164: 4804-4811.
109. Takahashi K, Morikawa A, Kato Y et al. Flavonoids protect mice against two types of lethal shock induced by endotoxin. FEMS Immunol Med Microbiol 2001; 31: 29-33.
110. Van-Dien M, Takahashi K, Mu MM et al. Protective effect of wogonin on endotoxin-induced lethal shock in D-galN-sensitized mice. Microbiol Immunol 2001; 45: 751-756.
111. Nicoletti F, Zaccone P, Di-Marco R et al. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology 1995; 85: 645-650.
112. Gorgen I, Hartung T, Leist M et al. Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-alpha. J Immunol 1992; 149: 918-924.
113. Nomi T, Shiota G, Isono M, Sato K, Kawasaki H. Adenovirus-mediated hepatocyte growth factor gene transfer prevents liver failure in rats. Biochem Biophys Res Commun 2000; 278: 338-343.
114. Bahrami S, Redl H, Buurman WA, Schlag G. Influence of the xanthine derivative HWA 138 on endotoxin-related coagulation disturbances: effects in non-sensitized vs D-galN sensitized rats. Thromb Haemost 1992; 68: 418-423.
115. Johnson DC, Freudenberg MA. Jia F, Gonzalez JC, Galanos C, Morrison DC. Contribution of tumor necrosis factor-alpha and glucocorticoid in hydrazine sulfate-mediated protection against endotoxin lethality. Circ Shock 1994; 43: 1-8.
116. Fomsgaard A, Galanos C. Protective properties of a human IgG preparation rich in antibodies to a wide spectrum of lipopolysaccharides. Acta Pathol Microbiol Immunol Scand 1989; 97: 1114-1120.
117. Libert C, Van-Bladel S, Brouckaert P, Shaw A, Fiers W. Involvement of the liver, but not of IL-6, in IL-1-induced desensitization to the lethal effects of tumor necrosis factor. J Immunol 1991; 146: 2625-2632.
118. Everaerdt B, Brouckaert P, Fiers W. Recombinant IL-1 receptor antagonist protects against TNF-induced lethality in mice. J Immunol 1994; 152: 5041-5049.
119. Baumhofer JM, Beinhauer BG, Wang JE et al. Gene transfer with IL-4 and IL-13 improves survival in lethal endotoxemia in the mouse and ameliorates peritoneal macrophages immune competence. Eur J Immunol 1998; 28: 610-615.
120. Barton BE, Shortall J, Jackson JV. Interleukins 6 and 11 protect mice from mortality in a staphylococcal enterotoxin-induced toxic shock model. Infect Immun 1996; 64: 714-718.
121. Donckier V, Flament V, Gerard C et al. Modulation of the release of cytokines and reduction of the shock syndrome induced by anti-CD3 monoclonal antibody in mice by interleukin-10. Transplantation 1994; 57: 1436-1439.
122. Santucci L, Fiorucci S, Chiorean M et al. Interleukin 10 reduces lethality and hepatic injury induced by lipopolysaccharide in galactosamine-sensitized mice. Gastroenterology 1996; 111: 736-744.
123. Rogy MA, Auffenberg T, Espat NJ et al. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med 1995; 181: 2289-2293.
124. Grundmann HJ, Hahnle U, Hegenscheid B et al. Inhibition of endotoxin-induced macrophage tumor necrosis factor expression by a prostacyclin analogue and its beneficial effect in experimental lipopolysaccharide intoxication. J Infect Dis 1992; 165: 501-505.
125. Qureshi N, Perera P-Y, Shen J et al. The proteasome, as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J Immunol 2003; 171: 1515-1525.
126. Zhang GH, Mann DM, Tsai CM. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 1999; 67: 1353-1358.
127. Gonzalo JA, Gonzalez-Garcia A, Kalland T, Hedlund G, Martinez C, Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol 1993; 23: 2372-2374.
128. Lam C, Schutze E, Walzl H, Basalka E. Protection of mice against lethal endotoxemia by lipid X is mediated through inhibition of neutrophil function. Circ Shock 1987; 22: 311-321.
129. David SA, Silverstein R, Amura CR, Kielian N, Morrison DC. Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by Gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 912-919.
130. Lamping N, Dettmer R, Schroder NW et al. LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101: 2065-2071.
131. Bozza M, Soares MB, Bozza PT et al. The PACAP-type I receptor agonist maxadilan from sand fly saliva protects mice against lethal endotoxemia by a mechanism partially dependent on IL-10. Eur J Immunol 1998; 28: 3120-3127.
132. Parmely MJ, Zhou WW, Edwards 3rd CK, Borcherding DR, Silverstein R, Morrison DC. Adenosine and a related carbocyclic analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 1993; 151: 389-396.
133. Borcherding DR, Peet NP, Munson HR et al. Carbocyclic nucleosides as inhibitors of human tumor necrosis factor-alpha production: effects of the stereoisomers of (3-hydroxycyclopentyl) adenines. J Med Chem 1996; 39: 2615-2620.
134. Quakyi EK, Frasch CE, Buller N, Tsai CM. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock. J Infect Dis 1999; 180: 747-754.
135. Wielockx B, Hochepied T, Staelens J, Van-Molle W, Brouckaert P, Libert C. Detection, characterisation and purification of a murine liver factor capable of desensitising towards the lethal activity of tumour necrosis factor. Cytokine 2001; 15: 59-65.
136. Evans TJ, Carpenter A, Moyes D, Martin R, Cohen J. Protective effects of a recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in an animal model of Gram-negative sepsis. J Infect Dis 1995; 171: 153-160.
137. Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996; 64: 4922-4927.
138. Zhang WJ, Wojta J, Binder BR. Notoginsensoside R1 counteracts endotoxin-induced activation of endothelial cells in vitro and endotoxin-induced lethality in mice in vivo. Arterioscler Thromb Vasc Biol 1997; 17: 465-474.
139. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31: 171-181.
140. Alegre ML, Gastaldello K, Abramowicz D et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991; 52: 674-679.
141. Badger AM, Olivera DL, Esser KM. Beneficial effects of the phosphodiesterase inhibitors BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circ Shock 1994; 44: 188-195.
142. Arrieta O, Ortiz-Reyes A, Rembao D, Calvillo M, Rivera E, Sotelo J. Protective effect of pentoxifylline plus thalidomide against septic shock in mice. Int J Exp Pathol 1999; 80: 11-16.
143. Oku H, Nakazato H, Horikawa T, Tsuruta Y, Suzuki R. Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002; 446: 167-176.
144. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Morgolin S, Lefkowitz SS. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998; 20: 685-695.
145. Drabick JJ, Bhattacharjee AK, Hoover DL et al. Covalent polymyxin B conjugate with human immunoglobulin G as an antiendotoxin agent. Antimicrob Agents Chemother 1998; 42: 583-588.
146. Bucklin SE, Lake P, Logdberg L, Morrison DC. Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia. Antimicrob Agents Chemother 1995; 39: 1462-1466.
147. Schutze E, Hildebrandt J, Liehl E, Lam C. Protection of mice from mortality caused by living and heat-killed bacteria by SDZ MRL 953. Circ Shock 1994; 42: 121-127.
148. Sakaguchi S, Tutumi E, Yokota K, Furusawa S, Sasaki K, Takayanagi Y. Preventive effects of a Chinese herb medicine (sho-saiko-to) against lethality after recombinant human tumor necrosis factor administration in mice. Microbiol Immunol 1991; 35: 389-394.
149. Olivera DL, Esser KM, Lee JC, Greig RG, Badger AM. Beneficial effects of SK&F 105809, a novel cytokine-suppressive agent, in murine models of endotoxin shock. Circ Shock 1992; 37: 301-306.
150. Lesslauer W, Tabuchi H, Gentz R et al. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 1991; 21: 2883-2886.
151. Bourrie B, Bouaboula M, Benoit JM et al. Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand. Eur J Immunol 1995; 25: 2882-2887.
152. Yamazaki H, Harada H, Matsuzaki K, Watanabe T, Saito H. Synthesis of 3-substituted 2-oxo-1,4 thiazines and evaluation of their protective effect against endotoxin shock in mice. Chem Pharm Bull 1992; 40: 1025-1028.
153. Alcorn JM, Fierer J, Chojkier M. The acute phase response protects mice from D-galN sensitization to endotoxin and tumor necrosis factor-alpha. Hepatology 1992; 15: 122-129.
154. Ogura S, Umegaki O, Genovese F et al. Protective effect of tyrphostin AG-556 on shock induced by endotoxin or Gram-positive bacteria. Shock 1999; 12: 105-110.
155. Bucklin SE, Silverstein R, Morrison DC. An interleukin-6-induced acute-phase response does not confer protection against lipopolysaccharide lethality. Infect Immun 1993; 61: 3184-3189.
156. Morikawa A, Kato T, Sugiyama et al. Altered expression of constitutive type and inducible heat shock proteins in response of D-galactosamine-sensitized mice to lipopolysaccharide as an experimental endotoxic shock model. FEMS Immunol 1998; 21: 37-45.
157. McCallum RE. Hepatocyte-Kupffer cell interactions in the inhibition of hepatic gluconeogenesis by bacterial endotoxins. In: Person RJ, Majde JA. (eds) Pathophysiological Effects of Endotoxins at the Cellular Level. New York, NY: Liss, 1981; 99-113.
158. McCallum RE, Seale TW, Stith RD. Influence of endotoxin treatment on dexamethasone induction of hepatic phosphoenolpyruvate carboxykinase. Infect Immun 1983; 39: 213-219.
159. Stith RD, McCallum RE. Failure of glucagon to induce hepatic phosphoenolpyruvate carboxykinase in endotoxic shock. Circ Shock 1988; 26: 267-272.
160. Topaloglu AK, Goto M, Ravindranath T, Zeller WP. Galactosamine alters glucose regulation in ten-day-old rats treated with a low dose of endotoxin. Res Commun Mol Pathol Pharmacol 1996; 91: 297-302.
161. Ravindranath T, Topaloglu AK, Goto M, Zeller WP. Effects of hydrazine sulfate on galactosamine-sensitized endotoxic shock in ten-day-old rats. Res Commun Mol Pathol Pharmacol 1998; 99: 233-239.
162. Underhill FP. Studies in carbohydrate metabolism. I. The influence of hydrazine upon the organism, with special reference to the blood sugar content. J Biol Chem 1911; 10: 159-168.
163. Ray PD, Hanson RL, Lardy HA. Inhibition by hydrazine of gluconeogenesis in the rat. J Biol Chem 1970, 245: 690-696.
164. Shnyra A, Luchi M, Gao J et al. Endotoxin in human disease and its endogenous control. In: Baue AE, Faist E, Fry DE. (eds) Multiple Organ Failure: Pathology, Prevention, and Therapy. Berlin: Springer, 2000, 114-130.
165. 1-antitrypsin-deficient rat model. Am Rev Respir Dis 1984; 130: 231-236.
166. 1-antitrypsin deficiency and increased susceptibility to elastase-induced experimental emphysema in a rat model. Am Rev Respir Dis 1979; 120: 1375-1379.
167. Luchi M, Morrison DC. Comparable endotoxic properties of lipopolysaccharides are manifest in diverse clinical isolates of Gram-negative bacteria. Infect Immun 2000; 68: 1899-1904.
168. Levin J, Bang FB. Clottable protein in Limulus: its localization and kinetics of its coagulation by endotoxin. Thromb Diath Haemorrh 1968; 19: 186-197.
169. Levin J, Tomasulo PA, Oser RS. Detection of endotoxin in human blood and demonstration of an inhibitor. J Lab Clin Med 1970; 75: 903-911.
170. Galanos C, Lüderitz O, Rietschel ETh et al. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 1985; 148: 1-5.
171. Rietschel ETh, Brade L, Lindner B, Zähringer U. Biochemistry of lipopolysaccharides. In: Morrison DC, Ryan JL. (eds) Bacterial Endotoxic Lipopolysaccharides, vol I. Boca Raton, FL: CRC Press, 1992; 3-41.
172. Takayama K, Qureshi N. Chemical structure of lipid A. In: Morrison DC, Ryan JL. (eds) Bacterial Endotoxic Lipopolysaccharides, vol I. Boca Raton, FL: CRC Press, 1992; 43-65.
173. Matsuura M, Yamamoto A, Kojima Y, Homma JY, Kiso M, Hasegawa W. Biological activities of chemically synthesized partial structure analogues of lipid A. J Biochem 1985; 98: 1229-1237.
174. Kotani S, Takada H, Tsujimoto M et al. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli Re-mutant. Infect Immun 1985; 49: 225-237.
175. Takada H, Kotani S, Tsujimoto H et al. Immunopharmacological activities of a synthetic counterpart of a biosynthetic lipid A precursor molecule and its analogs. Infect Immun 1985; 48: 219-227.
176. Homma JY, Matsuura M, Kanegasaki Y et al. Structural requirements of lipid A responsible for the functions: a study with chemically synthesized lipid A and its analogues. J Biochem 1985; 98: 395-406.
177. Kotani S, Takada H, Takahashi I et al. Immunobiological activities of synthetic lipid A analogues with low endotoxicity. Infect Immun 1986; 54: 673-682.
178. Takahashi I, Kotani S, Takada H et al. Requirement of a properly acylated beta (1-6)-D-glucosamine disaccharide bisphosphate structure for efficient manifestation of full endotoxic and associated bioactivities of lipid A. Infect Immun 1987; 55: 57-68.
179. Kumazawa Y, Nakatsuka M, Takimoto H et al. Importance of fatty acid substituents of chemically synthesized lipid A-subunit analogs in the expression of immunopharmacological activity. Infect Immun 1988; 56: 149-155.
180. Shimizu T, Masuzawa T, Yanagihara Y, Nakamoto S, Itoh H, Achiwa K. Antitumor activity, mitogenicity, and lethal toxicity of chemically synthesized monosaccharide analogs of lipid A. J Pharmacobiodyn 1988; 11: 512-518.
181. Shimizu T, Masuzawa T, Yanagihara Y, Shimizu C, Ikeda K, Achiwa K. Biological activities of chemically synthesized N-acetylneuraminic acid-(alpha 2-6)-monosaccharide analogs of lipid A. FEBS Lett 1988; 228: 99-101.
182. Shimizu T, Ohtsuka Y, Masuzawa T et al. Antitumor activity against Meth A fibrosarcoma and biologic activities of synthetic monosaccharide analogs of lipid A in mice. Mol Biother 1990; 2: 110-114.
183. Johnson AG, Tomai MA, Chen YF, Odean M. A comparison of the immunomodulating properties of two forms of monophosphoryl lipid A analogues. J Immunother 1991; 10: 398-404.
184. Masoud H, Weuntraub ST, Wang R, Cotter R, Holt SC. Investigation of the structure of lipid A from Actinobacillus actinomycetemcomitans strain Y4 and human clinical isolate PO 1021-7. Eur J Biochem 1991; 200: 775-781.
185. Lam C, Schutze E, Hildebrandt J et al. SDZ MRL 953, a novel immunomodulatory monosaccharidic lipid A analog with an improved therapeutic window in experimental sepsis. Antimicrob Agents Chemother 1991; 35: 500-505.
186. Ogawa T. Immunological properties of chemically defined lipid A from lipopolysaccharide of Porphyromonas (Bacteroides) gingivalis. Eur J Biochem 1994; 219: 737-742.
187. Moran AP. Biological and serological characterization of Campylobacter jejuni lipopolysaccharides with deviating core and lipid A structures. FEMS Immunol Med Microbiol 1995; 11: 121-130.
188. Matsuura M, Shimada S, Kiso M, Hasgawa A, Nakano M. Expression of endotoxic activities by synthetic monosaccharide lipid A analogs with alkyl-branched acyl substituents. Infect Immun 1995; 63: 1446-1451.
189. Shimizu T, Iida K, Iwamoto Y et al. Biological activities and antitumor effects of synthetic lipid A analog linked N-acylated serine. Int J Immunopharmacol 1995; 17: 425-431.
190. Shimizu T, Iwamoto Y, Yanagihara Y et al. Comparison of the biological activity of synthetic N-acylated asparagine or serine linked monosaccharide lipid A analogs. Immunobiology 1996; 196: 321-331.
191. Ogawa T, Suda Y, Kashihara W et al. Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine 1997; 15: 1598-1605.
192. Tanamoto K, Azumi S, Haishima Y, Kumada H, Umemoto T. Endotoxic properties of free lipid A from Porphyromonas gingivalis. Microbiology 1997; 143: 63-71.
193. Sagara-Ishijima N, Furuhama K. Toxic characteristics of the synthetic lipid A derivative DT-5461 in rats and monkeys. Toxicol Sci 1999; 49: 324-331.
194. Johnson DA, Keegan DS, Sowell CG et al. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J Med Chem 1999; 42: 4640-4649.
195. Suda Y, Kim Y, Ogawa T et al. Chemical structure and biological activity of a lipid A component from Helicobacter pylori strain 206. J Endotoxin Res 2001; 7: 95-104.
196. Tanamoto K, Kato H, Haishima Y, Azumi S. Biological properties of lipid A isolated from Flavobacteriun meningosepticum. Clin Diagn Lab Immunol 2001; 8: 522-527.
197. Tanamoto K, Iida T, Haishima Y, Azumi S. Endotoxic properties of lipid A from Comamonas testosteroni. Microbiology 2001; 147: 1087-1094.
198. Riedemann NC, Guo R-F, Ward P.A. The enigma of sepsis. J Clin Invest 2003; 112: 460-467.